TriSalus Life Sciences, Inc.
TLSI
$5.73
$0.081.42%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 49.39% | -20.12% | -3.39% | -35.16% | -25.80% |
| Total Depreciation and Amortization | 8.77% | 70.87% | 62.31% | 124.10% | 71.86% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -134.44% | 514.78% | -51.72% | 14.93% | -37.88% |
| Change in Net Operating Assets | -1,878.21% | -25,570.83% | -219.74% | -84.17% | -76.65% |
| Cash from Operations | 19.25% | 10.86% | -65.22% | -58.08% | -56.53% |
| Capital Expenditure | 41.33% | -58.81% | -130.72% | -65.05% | 10.23% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | 0.00% | 0.00% | 0.00% | 0.00% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | 1,570.59% | 137.50% | 197.10% | 100.00% |
| Cash from Investing | 78.27% | 55.17% | -9.60% | -8.15% | 11.09% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 3.45% | 54.69% | 49.12% | 42.76% | 33.59% |
| Issuance of Common Stock | 8,622.35% | 10,930.43% | 7,206.38% | 3,848.19% | 90.43% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -100.00% | -81.45% | -48.99% | 39.41% |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -107.26% | -107.31% | -- | -- | -- |
| Cash from Financing | -30.56% | -42.17% | 186.45% | 133.57% | 305.80% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -232.03% | -207.53% | 219.57% | 78.17% | 111.93% |